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Mast cells regulate CD41 T-cell differentiation in
the absence of antigen presentation
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Background: Given their unique capacity for antigen uptake,
processing, and presentation, antigen-presenting cells (APCs)
are critical for initiating and regulating innate and adaptive
immune responses. We have previously shown the role of
nicotinamide adenine dinucleotide (NAD1) in T-cell
differentiation independently of the cytokine milieu, whereas
the precise mechanisms remained unknown.
Objective: The objective of this study is to further dissect the
mechanism of actions of NAD1 and determine the effect of
APCs on NAD1-mediated T-cell activation.
Methods: Isolated dendritic cells and bone marrow–derived
mast cells (MCs) were used to characterize the mechanisms of
action of NAD1 on CD41 T-cell fate in vitro. Furthermore,
NAD1-mediated CD41 T-cell differentiation was investigated
in vivo by using wild-type C57BL/6, MC2/2, MHC class II2/2,
Wiskott-Aldrich syndrome protein (WASP)2/2, 5C.C7
recombination-activating gene 2 (Rag2)2/2, and CD11b-DTR
transgenic mice. Finally, we tested the physiologic effect of
NAD1 on the systemic immune response in the context of
Listeria monocytogenes infection.
Results: Our in vivo and in vitro findings indicate that after
NAD1 administration, MCs exclusively promote CD41 T-cell
differentiation, both in the absence of antigen and
independently of major APCs. Moreover, we found that MCs
mediated CD41 T-cell differentiation independently of MHC II
and T-cell receptor signaling machinery. More importantly,
although treatment with NAD1 resulted in decreased MHC II
expression on CD11c1 cells, MC-mediated CD41 T-cell
differentiation rendered mice resistant to administration of
lethal doses of L monocytogenes.
Conclusions: Collectively, our study unravels a novel cellular
and molecular pathway that regulates innate and adaptive
immunity through MCs exclusively and underscores the
therapeutic potential of NAD1 in the context of primary
immunodeficiencies and antimicrobial resistance. (J Allergy
Clin Immunol 2018;142:1894-908.)
Key words: Nicotinamide adenine dinucleotide, mast cells, T cells,
antigen presentation, MHC, T-cell receptor, CD41 T-cell differenti-
ation, dendritic cells, macrophages, Listeria monocytogenes,
cytokine
Antigen-presenting cells (APCs) play a central role in regulation
of the innate and adaptive immune responses.1 APCs have the abil-
ity to capture, process, and present antigens through their MHC
cell-surface molecules to the T-cell receptor (TCR) to mount an
MHC-restricted immune response.2-6 APCs include a myriad of
immune cells, such as B cells, neutrophils, macrophages, eosino-
phils, basophils, and dendritic cells (DCs). Among these popula-
tions, DCs are considered the major APCs bridging innate and
adaptive immune responses.7,8 The mode of action of DCs is medi-
ated through at least 3 signals: (1) TCR activation, (2) activation of
costimulatory molecules, and (3) secretion of chemokines and
proinflammatory cytokines.8 Indeed, depletion of CD11c1 DCs
has been shown to alter cytotoxic T-lymphocyte responses to infec-
tion, aswell asCD41T-cell activation and antibody production.9 In
addition, DCs can also regulate innate and adaptive immune re-
sponses by recognizing pathogen-associated molecular patterns
(PAMPs), such as microbial nucleic acids, lipoproteins, and carbo-
hydrates, or damage-associated molecular patterns (DAMPs)
released from injured cells through intracellular or surface-
expressed pattern recognition receptors (PRRs).10-14
Although considered ‘‘atypical’’ APCs, Mast cells (MCs) have
been described mainly for their role in allergic and autoimmune
responses.15,16 It is well established that MCs are important
effector cells in IgE-mediated allergic inflammation, and MCs
are also recognized to influence innate and adaptive immune
responses.8,16
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Abbreviations used
APC: Antigen-presenting cell
BMMC: Bone marrow–derived mast cell
DAMP: Damage-associated molecular pattern
DC: Dendritic cell
EAE: Experimental autoimmune encephalomyelitis
LPA: Lysophosphatidic acid
MC: Mast cell
NAD1: Nicotinamide adenine dinucleotide
PAMP: Pathogen-associated molecular pattern
PRR: Pattern recognition receptor
Rag2: Recombination-activating gene 2
TCR: T-cell receptor
WASP: Wiskott-Aldrich syndrome protein
WT: Wild-type
MC-deficient mice have been shown to exhibit an altered
CD41 T-cell response to infection and in experimental
autoimmune encephalomyelitis (EAE), amousemodel for human
multiple sclerosis, suggesting that MCs play a role in mediating
T-cell responses.17-20 Like DCs, MCs can directly present
antigens to T cells in vitro, inducing an antigen-specific clonal
expansion of T-cell populations, and are known to express costi-
mulatory molecules and secrete a myriad of chemokines and
proinflammatory cytokines.8,15,16,21 However, MCs express
MHC class II intracellularly rather than at the cell surface.22
Moreover, MCs have been shown to promote T-cell activation
in an antigen-independent manner, and no direct evidence has
been provided thus far on the capacity of direct antigen presenta-
tion to the TCR.8,23 Thus the mechanisms by whichMCs regulate
T-cell responses remain unclear and are yet to be determined.
Recently, we have shown the role of nicotinamide adenine
dinucleotide (NAD1), a cofactor found in all living cells and nutri-
ents, in T-cell fate regulation.24,25 We have demonstrated that
NAD1 was able to regulate CD41 T-cell differentiation through
a novel pathway that is independent of the cytokine environment
and well-established transcription factors.25 More recently, we
have reported the unique immunosuppressive properties mediated
byNAD1 through systemic IL-10 cytokine production.24Although
we characterized the role of NAD1 in regulating T-cell fate, the
precise mechanisms of action remain largely unknown.
Here we show that after NAD1 administration, MCs are able to
induce exclusively CD41T-cell differentiation in vitro and in vivo
in the absence of antigen and major APCs. Furthermore, we
demonstrate that MC-driven CD41 T-cell differentiation was in-
dependent of MHC class II or TCR activation. Furthermore, when
assessing the functional effect of MC-mediated CD41 T-cell dif-
ferentiation, we observed that treatment with NAD1 resulted in
profound alterations in innate and adaptive immunity and survival
outcome after Listeria monocytogenes infection. Collectively, our
study unravels a new cellular and molecular pathway regulating
innate and adaptive immune responses that is mediated
exclusively by MCs.
METHODS
Animals and diphtheria toxin treatment
Eight- to 10-week-old wild-type (WT) C57BL/6 (B6, H2b) mice
were purchased from Charles River Laboratories (Wilmington, Mass).
MC2/2 (WBB6F1/J-KitW/KitW-v/J [KitW/KitW-v] and KitW-sh/HNihrJaeBsmJ
[kitWsh/KitWsh]), MHC class II2/2 (B6.129S-H2dlAb1-Ea), Wiskott-Aldrich
syndrome protein (WASP)2/2 (B6.129S6-Wastm1Sbs/J), and CD11b-DTR
(B6.FVB-Tg[ITGAM-DTR/EGFP]34Lan/J) mice were purchased from
Jackson Laboratory (Bar Harbor, Me). Recombination-activating gene 2
(Rag2)2/2gc2/2 (B10; B6-Rag2tm1Fwa II2rgtm1Wjl), Rag22/2, and 5C.C7
Rag22/2 mice (both on B10.A background) were purchased from Taconic
Biosciences (Albany, NY). For CD11b1 cell depletion with diphtheria toxin
treatment, CD11b-DTR transgenic mice weighing 25 to 30 g were
injected with diphtheria toxin (25 ng/g body weight; Sigma-Aldrich, St Louis,
Mo) 24 hours before and 72 hours after beginning NAD1 or PBS
administration.
Isolation of mouse naive CD41CD442CD62L1 T cells
and DCs
Single-cell leukocyte suspensions were obtained from spleens of 8- to
10-week-old C57BL/6 mice, and naive CD41CD442CD62L1 T cells were
isolated by means of flow cytometry, as described previously.25 For isolation
of CD11c1 DCs, single-cell leukocyte suspensions were obtained from
spleens of 8- to 10-week-old C57BL/6WTmice. CD11c1DCs were then iso-
lated with the EasySep Mouse CD11c Positive Selection Kit (STEMCELL
Technologies, Vancouver, British Columbia, Canada), according to the
manufacturer’s protocol, followed by cell sorting (CD11c1CD11b1 cells).
L monocytogenes infection
L monocytogenes bacteria (ATCC #35152) were cultured overnight at 378C
inBrain Heart Infusion (Teknova, Hollister, CA) with gentle agitation. Eight- to
10-week-oldWTand MC2/2mice were infected intraperitoneally with 0.1 mL
of a solution containing 1 3 107 colony-forming units (nonlethal dose) or
1 3 108 colony-forming units (lethal dose) of viable L monocytogenes cells
in 0.01 mol/L PBS (pH 7.4). Weight loss and survival after infection were
monitored. Before infection, mice were pretreated daily for a period of 5 days
with NAD1 (40 mg administered intraperitoneally) or pretreated 5 days before
infection and continuously treated daily after infection.
Cultivation of bone marrow–derived mast cells
Bone marrow–derived mast cells (BMMCs) from 8- to 10-week-old
C57BL/6J WT mice were obtained by culturing bone marrow cells from
femurs and tibias. In short, mice were killed by means of cervical dislocation,
intact femurs and tibias were removed, and bone marrow cells were harvested
by means of repeated flushing with sterile media. BM cells were cultured in
WEHI-3–conditionedmedium (containing IL-3) for 90 days, at which time the
cells were greater than 95% c-KithighFcεRIahigh, as determined by using flow
cytometric analysis with PE-Cy7 anti-mouse FcεRIa (clone MAR-1;
eBioscience, San Diego, Calif) and ef450 anti-mouse c-Kit/CD117 (clone
2B8; eBioscience, San Diego, Calif).
Human MC line LAD-2 culture
The human MC line LAD-2 was a generous gift from Dr A. Kirshenbaum
(National Institutes of Health/National Institute of Allergy and Infectious
Diseases). LAD-2MCs were cultured in serum-free media (StemPro-34 SFM;
Life Technologies, Grand Island, NY) supplemented with 2 mmol/L L-gluta-
mine, 100 U/mL penicillin, 50 mg/mL streptomycin, and 100 ng/mL recombi-
nant stem cell factor. LAD-2 cells were tested periodically for expression of
Kit and FcεRI by using flow cytometry.
Cell culture
Isolated naive CD41 T cells or CD11c1 DCs (13 106 cells per well) were
cultured in 48-well flat-bottom plates in 0.5 mL of complete RPMI 1640
medium supplemented with 10% FCS, 200 mmol/L L-glutamine, 100 U/mL
penicillin/streptomycin, and 4.5 g/L glucose in the presence of 10 mg/mL
plate-bound anti-mouse a-CD3 (17A2) and 2 mg/mL soluble a-CD28
(37.51). NAD1 (catalog no. N3014; Sigma-Aldrich) was diluted in PBS and
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added as indicated. LPS was added at a concentration of 1 mg/mL. All recom-
binant cytokines and antibodies were purchased from eBioscience. After the
indicated day of culture, supernatants and cells were collected and analyzed
by means of ELISA and flow cytometry, respectively.
Coculture of mouse naive CD41 T cells and BMMCs
in transwell systems
Noncontacting cocultured cells were prepared as follows: isolated naive
CD41CD442CD62L1T cells were plated on the bottom of the 24-well trans-
well cell culture system (Costar, Cambridge, Mass). BMMCs were cocultured
at a ratio of 1:100 in the upper transwell compartment. Cells were stimulated
with NAD1 (500 mmol/L) or PBS as a control. Naive CD41 T cells were
cultured in complete media only or in the presence of 10 mg/mL
plate-bound anti-mouse a-CD3 (clone 17A2) and 2 mg/mL soluble a-CD28
(clone 37.51). For cell-cell contact experiments, BMMCs and naive
CD41CD442CD62L1 T cells were cocultured (at a ratio of 1:100) in
complete media with NAD1 (500 mmol/L) or PBS as a control. Naive
CD41 T cells were cultured in the presence of 10 mg/mL plate-bound
anti-mouse a-CD3 (clone 17A2) and 2 mg/mL soluble a-CD28 (clone
37.51) or complete media only. For CD80 blockade, experiments were
performed in cell-cell contact conditions, as described above, with a-CD80
neutralizing antibody (clone 16-10A1; eBioscience). Cells were cultured for
96 hours, and CD41IFN-g1, CD41IL-41, and CD41IL-17A1 T-cell
frequencies were assessed by using flow cytometry.
Isolation and coculture of human naive CD41 T cells
Human naiveCD41T cells were isolated fromPBMCs bymeans of density
gradient centrifugationwith the SepMate kit (STEMCELLTechnologies), fol-
lowed by the EasySep Human Na€ıve CD41 T Cell Isolation Kit (STEMCELL
Technologies). Blood was obtained from healthy adult volunteers in accor-
dance with guidelines of and approved by the Institutional Review Board of
Beth Israel Deaconess Medical Center. Informed consent was obtained from
each volunteer in accordance with the Declaration of Helsinki. Human naive
CD41CD252CD45RA1CD45RO2CCR71CD62L1T cells were then sorted
by means of flow cytometry. Naive CD41 T cells were purified to greater than
98% by using cell sorting. Naive human CD41 T cells were then plated on the
bottom of the 24-well transwell cell culture system (Costar), and LAD-2 cells
were cocultured at a ratio of 1:100 in the upper transwell compartment. Cells
were stimulated with NAD1 (500mmol/L) or PBS as a control. Naive CD41 T
cells were cultured in completemedia only or in the presence of 10mg/mL sol-
uble anti-mouse a-CD3 (clone 17A2) and 5 mg/mL soluble a-CD28 (clone
37.51). For cell-cell contact experiments, LAD-2 cells and naive
CD41CD442CD62L1 T cells were cocultured (at a ratio of 1:100) in com-
plete media with NAD1 (500 mmol/L) or PBS as a control. Naive CD41 T
cells were cultured in the presence of 10 mg/mL soluble anti-mouse a-CD3
(clone 17A2) and 5 mg/mL soluble a-CD28 (clone 37.51) or complete media
only. After 96 hours, CD41 T-cell IFN-g cytokine production was assessed by
using flow cytometry.
DC and macrophage depletion
For DC depletion, WT, Rag22/2gc2/2, and MC2/2 mice were treated
intravenously with 0.5 mg of liposomal clodronate (Encapsula NanoSciences,
Nashville, Tenn) at days 8, 5, and 1 before NAD1 administration. This
regimen ensured depletion of greater than 99% CD11c1 DCs, as described
previously.26,27 As a control group, mice were injected with the same amount
of isotype-matched rat IgG as control mice.
Flow cytometry
Fluorescence-labeled anti-mouse CD4 (clone GK1.5), CD11b (M1/70),
CD11c (N418), CD41 (eBioMWReg30), CD61 (2C9. G3), IL-1b (NJTEN3),
IL-4 (11B11), IL-6 (MP5-20F3), IL-10 (JES5-16E3), IL-12/IL-23p40 (C
17.8), IL-17 (eBio17B7), IFN-g (XMG 1.2), latency-associated peptide
(TW7-16B4), and TNF-a (MP6-XT22) were obtained from eBioscience.
All antibodies were used at a concentration of 2 to 5 mg per 13 106 cells. To
set the gates, flow cytometric dot plots were based on comparison with isotype
controls, fluorescence minus one, and permeabilized and unpermeabilized un-
stained cells. Intracellular staining for IL-1b, IL-4, IL-6, IL-10, IL-12/IL-
23p40, IL-17, IFN-g, latency-associated peptide, and TNF-a was performed
according to the manufacturer’s protocols. Cells were fixed and permeabilized
with Cytofix/Cytoperm solution (BD Biosciences, San Jose, Calif). Flow cy-
tometry was performed on a BD FACSCanto II (BD Biosciences) by using
standard procedures, and data were analyzed with FlowJo software (TreeStar,
Ashland, Ore).
ELISA
Mouse IL-4, IL-17A, and IFN-g levels were measured with commercial
kits (eBioscience), as described previously.24,25
RNA extraction and quantitative PCR
BMMCs from C57BL/6 mice were cultured in the presence of NAD1
(500 mmol/L), LPS, or placebo (PBS). After 24 hours of culture, cells were
collected, and mRNAwas extracted by using the RNAqueous extraction kit,
according to the manufacturer’s protocols (Applied Biosystems, Foster City,
Calif). Briefly, cells were homogenized in lysis buffer (total volume of
0.5 mL) and passed through a column. After successive washes, RNA was
eluted. For real-time PCR reactions, IL-1a (Mm00439620_m1), IL-b
(Mm01336189_m1), IL-4 (Mm00445259_m1), IL-6 (Mm004446190_m1),
IL-10 (Mm00439616_m1), IL-12a (Mm00434165_m1), IL-23 (Mm00
518984_m1), TGF-b1 (Mm01178820_m1), TNF-a (Mm00443260_g1),
TLR2 (Mm00442346_m1), TLR4 (Mm00445273_m1), CD86 (Mm00
444543_m1), CD80 (Mm00711660_m1), inducible costimulator ligand
(Mm00497237_m1), OX40 ligand (Mm00437214_m1), and IL-33 (Mm00
505403_m1) measurements were performed with TaqMan primers and probes
from Applied Biosystems. The housekeeping gene glyceraldehye-
3-phosphate dehydrogenase (Mm99999915_g1) was used as a control.
FIG 1. NAD1 induces T-cell activation in vivo and T-cell differentiation in vitro after TCR activation. A,
C57BL/6 mice were treated daily with intraperitoneal injection of 40 mg of NAD1 or a placebo solution
(PBS). After 7 days, mice were killed, and CD41 T cells were isolated from spleens. Frequencies and total
numbers of CD41IFN-g1, CD41IL-41, and CD41IL-17A1 cells were analyzed by using flow cytometry. B,
CD41 T cells (3 3 106) from 5C.C7 RAG-2–deficient mice were injected into Rag22/2 (B10.A background)
mice as adoptive transfer recipients. Mice were then treated with NAD1 or PBS for 7 days and subsequently
killed to analyze frequencies and total numbers of CD41IFN-g1 cells by using flow cytometry. C and D,
Sorted naive CD41CD442CD62L1 T cells were isolated from spleens of C57BL/6 mice and cultured in com-
plete media alone with a-CD3/a-CD28 with or without IL-2 or in the presence of 50 mmol/L NAD1. After
96 hours, frequencies of CD41IFN-g1 cells and IFN-g, IL-4, and IL-17A cytokine secretion were assessed
by using flow cytometry (Fig 1, C) and ELISA (Fig 1, D), respectively. Statistics were as follows: n 5 15
(Fig 1, A and B) or n 5 10 (Fig 1, C and D). Data were derived from 3 independent sets of experiments.
The Student t test and ANOVA were used accordingly to compare groups: **P < .01 and ***P < .001.
Data are presented as means 6 SDs. FACS, Fluorescein-activated cell sorting; FITC, fluorescein isothiocya-
nate; PE, phycoerythrin.
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RNA sequencing analysis
BMMCs from C57BL/6 mice were cultured in the presence of NAD1
(500 mmol/L), LPS (10 mg/mL; Escherichia coli O127:B8), or placebo
(PBS). After 16 hours of culture, cells were collected and RNAwas extracted
with the RNAqueous extraction kit, according to the manufacturer’s protocols
(Applied Biosystems), as described above. cDNAwas obtained by using New
England Biolabs kits (NEBNext Ultra Directional RNA Library Prep Kit for
Illumina; NewEnglandBiolabs, Ipswich,Mass). Briefly,mRNAwas extracted
with polyT magnetic beads, and then first- and second-strand syntheses were
performed. Once double-strand cDNA was generated, DNA was cleaned up
with magnetic beads and then went into library prep. Library preparation
was performed by ligating on the P5 and P7 Illumina adaptors along with
an index and amplifying the sequencing library by using PCR. The final library
was cleaned up by using magnetic beads and made ready for sequencing.
FastQ files were aligned against the Ensembl GRCm38.75 genome by using
the STAR aligner (version 2.3.1z4) with default parameters.28 Alignment files
(BAM format) were filtered to retain only primary alignments (Samtools view-
F 0x0100) and inspected for duplication rate with Picard tools MarkDupli-
cates; for downstream analyses, duplicate reads were not removed because
of the high-quality input RNA.29 Reads were quantified at the gene level by
using featureCounts with annotated exon features in the Ensembl
GRCm38.75 GTF file.30,31 The resulting count matrix was normalized and
analyzed for differential expression with DESeq2 software. Ingenuity Path-
ways Analysis (Ingenuity Systems, Redwood City, Calif) applications were
used to generate canonical pathways.
Statistical analysis
Data are presented as means6 SDs. Statistical analysis was done with the
2-tailed Student t test (between 2 groups) and 1-wayANOVA (amongmultiple
groups), where appropriate. Survival was compared by using the log-rank test.
P values of less than .05 were considered statistically significant.
Study approval
Animal care and use were in accordance with the National Institutes of
Health and Institutional Animal Care and Use Committee guidelines.
RESULTS
NAD1 requires an intermediary signal to promote
CD41 T-cell differentiation
We have demonstrated previously that NAD1 regulated CD41
T-cell differentiation independently of the cytokine milieu and
well-established transcription factors.25 It remains unclear
whether NAD1 promotes CD41 T-cell differentiation by acting
directly on CD41 T cells or through an intermediate cell type.
C57BL/6 WT naive mice were treated daily with intraperitoneal
injection of NAD1 or a placebo solution (PBS) and CD41
T-cell responses were assessed to characterize the direct effect
of NAD1 on CD41 T cells in the absence of antigen challenge.
After 7 days, mice were killed, and systemic CD41IFN-g1,
CD41IL-41, and CD41IL-17A1 T-cell frequencies were
evaluated by using flow cytometry. Data indicated that NAD1
administration was sufficient to promote a significant increase
in frequencies of CD41IFN-g1, CD41IL-41, and CD41IL-171
T cells in vivo (Fig 1, A). Of note, NAD1 administration to
Rag22/2 mice adoptively transferred with naive CD41 T cells
from Rag 5C.C7 transgenic mice promoted CD41IFN-g1
T-cell differentiation in the absence of moth cytochrome C
peptide challenge (Fig 1, B).
Thus we next assessed in vitro whether NAD1 directly pro-
motes CD41 T-cell differentiation and cytokine production.
Splenic naive CD41CD442CD62L1 T cells from C57BL/6 WT
mice were cultured in the presence or absence of a-CD3/a-
CD28 with or without IL-2 and in the presence of NAD1 or
PBS. After 96 hours of culture, CD41 T cells were assessed for
IFN-g, IL-4, and IL-17 production by using flow cytometry and
ELISA. Consistent with our previous reports, flow cytometry re-
vealed that NAD1 promotes a robust increase of CD41IFN-g1 T-
cell frequencies after TCR activation, particularly in the presence
of IL-2 (Fig 1, C). These findings were confirmed by means of
ELISA, indicating increased IFN-g, IL-4, and IL-17 production
after CD3/CD28 activation (Fig 1, D). Of note, the highest
CD41IL-171 T-cell frequencies and IL-17 secretion were
observed after TCR activation and in the absence of IL-2, which
was consistent with previous reports indicating that IL-2 inhibits
TH17 development. In contrast, no changes in CD4
1IFN-g1
T-cell frequencies or IFN-g, IL-4, and IL-17 cytokine production
were observed with NAD1 treatment in the absence of TCR
activation (Fig 1, C and D). Furthermore, increasing NAD1 con-
centrations in the absence of TCR activation did not result in a
change in CD41IFN-g1, CD41IL-41, and CD41IL-171 T-cell
frequencies (see Fig E1, A, in this article’s Online Repository at
www.jacionline.org). Collectively, our in vivo data indicate that
NAD1 promotes CD41T-cell differentiation in the absence of an-
tigen challenge, whereas our in vitro data indicate that NAD1 re-
quires TCR activation, suggesting that NAD1-mediated CD41 T-
cell differentiation observed in C57BL/6 WT naive mice requires
an intermediary signal.
NAD1 regulates CD41 T-cell fate in the absence of
major APCs
We next investigated whether other immune cells that are
known to activate CD41 T cells, in particular APCs, are involved
in NAD1-mediated CD41 T-cell differentiation. It has been
shown that ATP, a coenzyme, can promote TH17 cells through
IL-6, IL-23, and TGF-b cytokine production by CD11c1 cells.32
Because NAD1 also acts as a coenzyme, we first assessed in vitro
the effects of NAD1 on CD11c1 DCs. CD11b1CD11c1 DCs
were isolated from spleens of C57BL/6 mice and cultured in
the presence of increasing NAD1 concentrations or PBS. As a
positive control, CD11b1CD11c1DCs were cultured in the pres-
ence of 1 mg/mL LPS. After 16 hours, cells were collected and
cytokine expression was quantified by using real-time PCR.
Consistent with numerous reports, stimulation of
CD11b1CD11c1 cells by LPS resulted in increased mRNA
expression levels of IL-1a, IL-1b, IL-6, IL-23, and TNF-a but
not IL-12 and a downregulation of TLR4.33,34 More importantly,
in the presence of NAD1, CD11c1CD11b1 DCs exhibited
increased mRNA expression levels of IL-1a, IL-1b, IL-6, IL-
10, IL-12, IL-23, TGF-b1, TNF-a, TLR2, and TLR4 in a dose-
dependent manner (see Fig E1, B), suggesting that NAD1 alters
CD11b1CD11c1 DC activation.
Thus we next assessed whether NAD1 administration can
induce CD11c1CD11b1 DC activation in vivo as well. C57BL/
6 WT mice were treated daily with 40 mg of NAD1 or PBS by
means of intraperitoneal injection. Consistent with our in vitro
findings, we found that NAD1-treated WT mice showed
increased cytokine production, including IL-1b, IL-4, IL-6, IL-
10, IL-12, TGF-b1, and TNF-a, by CD11b1CD11c1 cells
when compared with levels in PBS-treated WT mice (Fig 2).
This is consistent with a previous study indicating that
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FIG 2. NAD1 treatment induces increased cytokine production by CD11b1CD11c1DCs in vivo. C57BL/6mice
were treated daily with intraperitoneal injection of 40 mg of NAD1 or a placebo solution (PBS). After 7 days,
mice were killed, and CD11b1CD11c1 DCs were isolated from spleens. Frequencies of CD11c1IL-1b1,
CD11c1IL-41, CD11c1IL-61, CD11c1IL-101, CD11c1IL-121, CD11c1TGF-b1, and CD11c1TNF-a1 cells were
analyzed by using flow cytometry. Statistics were as follows: n5 15. Data were derived from 3 independent
sets of experiments. Data are presented as means 6 SDs. The Student t test was used to compare groups:
***P < .001. APC, Allophycocyanin; PE, phycoerythrin.
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intracellular NAD1 levels regulate TNF-a cytokine production.35
Taken together, our in vitro and in vivo data indicated that NAD1
promotes CD11b1CD11c1 DC activation and cytokine produc-
tion and might play a central role in NAD1-mediated CD41 T-
cell differentiation.
It is well established that DCs can promote CD41 T-cell differ-
entiation through cytokine and chemokine release. Moreover, like
NAD1, ATP, a cofactor in energy metabolism, has been shown to
enhance IL-6, IL-23, and TGF-b cytokine production by CD11c1
cells and promote a TH17 response.
32 Because our results indi-
cated that NAD1 promotes cytokine expression by
CD11b1CD11c1 DCs, we tested whether CD41 T-cell differen-
tiation resulted from NAD1-mediated DC activation. As reported
by us and others,26,27 more than 99% of professional phagocytes,
including both DCs and macrophages, were depleted in WT mice
by means of injection of clodronate liposomes (see Fig E2, A, in
this article’s Online Repository at www.jacionline.org). As shown
in Fig E2, B, DC depletion did not abolish CD41IFN-g1,
CD41IL-41, and CD41IL-171 differentiation. These data sug-
gest that NAD1 regulates CD41 T-cell differentiation indepen-
dently of DCs and macrophages.
Although NAD1-mediated CD41 T-cell differentiation was
not abolished after macrophage and DC depletion, we could
not rule out compensation by other APCs, such as B cells. To
characterize the role of B cells in NAD1-mediated CD41
T-cell differentiation, we used transgenic Rag22/2gc2/2 mice,
which lack B, natural killer, and gd T cells. In addition,
Rag22/2gc2/2 mice were subjected to depletion of DCs and
macrophages. After depletion (see Fig E2, A), Rag22/2gc2/2
mice received adoptive transfer of naive CD41CD442CD62L1
T cells and were subjected to treatment with NAD1 or placebo
solution. The results indicated that NAD1 induced a significant
increase in numbers of CD41IFN-g1, CD41IL-41, CD41IL-
171, and CD41IL-101 cells when compared with the control
group of mice treated with a placebo solution (see Fig E3, A,
in this article’s Online Repository at www.jacionline.org).
Moreover, treatment with diphtheria toxin of CD11b-DTR
transgenic mice did not abolish CD41IFN-g1, CD41IL-41,
and CD41IL-171 differentiation (see Fig E3, B). Taken
together, our results indicate that NAD1 promotes CD41
T-cell differentiation independently of B cells in addition to
macrophages and DCs.
NAD1 administration regulates CD41 T-cell fate
through MCs exclusively
MCs have been mainly described for their role in allergic and
autoimmune responses.8,15,16 Although MCs express costimula-
tory molecules and secrete a myriad of chemokines and proin-
flammatory cytokines and have been shown to influence T-cell
polarization, the mechanisms by which MCs regulate T-cell
response remain unclear. Indeed, previous studies have reported
that MC-deficient mice display defective CD41 but also CD81
T-cell responses after Leishmania major infection36 and in the
setting of EAE.37 Furthermore, we have shown previously that
NAD1 protects against EAE.25 Thus we next investigated the
role of MCs in NAD1-mediated CD41 T-cell differentiation.
WT and MC-deficient mice (KitW/KitW-v) were treated daily
with intraperitoneal injection of NAD1. Treatment with NAD1
in MC-deficient mice was not able to promote CD41IFN-g1,
CD41IL-41, and CD41IL-171 T cells, indicating that MCs
were required for NAD1-mediated CD41 T-cell differentiation
(Fig 3).
Therefore we next sought to dissect the role of MCs in NAD1-
mediated T-cell differentiation in vitro. BMMCs were generated,
as described in the Methods section. The average yield of MCs
(FcεRI1c-Kit1 double-positive cells) increased with time and
reached greater than 95% on day 90, as shown by using flow cy-
tometry (see Fig E3, C). BMMCs were cultured over 6 weeks to
express homogenous levels of KIT and FcεRI.8 BMMCs were
then directly cocultured with naive CD41CD442CD62L1T cells
in the presence of NAD1 or PBS. Moreover, MCs and T cells
were cocultured in separate compartments by using a transwell
system to determine whether these cells require cell-cell contact.
As an additional control, naive CD41CD442CD62L1 T cells
were activated with a-CD3/a-CD28. The results indicated that
in the presence of NAD1, MCs promoted CD41IFN-g1,
CD41IL-41, and CD41IL-171 T-cell differentiation in the
absence of TCR activation (media plus NAD1) and indepen-
dently of cell-cell contact (see Fig E4 in this article’s Online Re-
pository at www.jacionline.org). Moreover, when MCs and naive
CD41CD442CD62L1T cells were cocultured in the presence of
NAD1 and T cells were activated with a-CD3/a-CD28, fre-
quencies of CD41IFN-g1 and CD41IL-171 T cells increased
further (see Fig E4). These results were consistent with our initial
findings indicating that cultured naive CD41CD442CD62L1 T
cells in the presence of NAD1 and a-CD3/a-CD28 promoted
CD41IFN-g1, CD41IL-41, and CD41IL-171 (Fig 1, C and D).
Like DCs, MCs express costimulatory molecules and secrete a
myriad of cytokines that are known to regulate innate and
adaptive immune responses. Thus to determine whether MCs
mediate CD41 T-cell differentiation through costimulatory mol-
ecules, cytokines, or both, MCs were treated with NAD1
in vitro, and mRNA levels of OX40 ligand, inducible costimulator
ligand, CD80, CD86, TNF-a, IL-4, IL-6, and IL-33 were
measured by using real-time PCR. NAD1 induced a modest in-
crease in CD80 and IL-33 and a decrease in IL-4 mRNA expres-
sion levels by MCs (see Fig E5, A, in this article’s Online
Repository at www.jacionline.org). It is well established that
CD80 can either promote or inhibit activation of naive T cells
by binding to CD28 or cytotoxic T lymphocyte–associated anti-
gen 4, respectively. Therefore to assess the role of CD80 in
NAD1-MC–mediated CD41 T-cell differentiation, blockade of
CD80 with a neutralizing antibody was performed in vitro by us-
ing our cell-cell contact coculture system. Our findings indicated
that CD80 blockade did not reduce CD41IFN-g1 or CD41IL-
171 T-cell frequencies when compared with an isotype control
(see Fig E5, B and C). Of note, CD80 blockade resulted in
increased CD41IL-41 T-cell frequencies (see Fig E5, D), sug-
gesting that CD80 can play an inhibitory effect on MC-
mediated IL-4 cytokine production. Collectively, our findings
suggest that MC-mediated CD41 T-cell differentiation does not
require cell-cell contact or involvement of conventional costimu-
latory molecules, such as CD80.
MC-mediated CD41 T-cell differentiation is
conserved in the human MC line LAD-2
We next investigated whether this novel pathway is conserved
in human subjects and whether humanMCs could regulate human
CD41T-cell differentiation as well. Naive CD41T cells were iso-
lated from healthy donors and cocultured in direct contact or in
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our transwell system with LAD-2 cells, a well-established human
MC line. Similar to murine BMMCs, cocultures were performed
in the presence of NAD1 or PBS and with or without a-CD3/a-
CD28. Flow cytometry indicated that in the presence of NAD1,
human MCs promoted CD41IFN-g1 T-cell differentiation (see
Fig E6, A, in this article’s Online Repository at www.jacionline.
org). Consistent with our murine BMMC data, human MCs
were able to promote TH1 polarization in the absence of cell-
cell contact. Taken together, these results suggest that the MC-
mediated CD41 T-cell differentiation pathway through MCs is
conserved in human subjects as well.
Unique gene expression profile by MCs after NAD1
activation
To unravel a potential signaling pathway involved in MC-
mediated CD41 T-cell differentiation, we next performed an
RNA-sequencing analysis on BMMCs that were cultured for
16 hours in the presence of NAD1, LPS, or PBS. As shown in
Fig 4, A, the results indicated that NAD1 significantly upregu-
lated 603 genes and downregulated 753 genes (with a P value
of less than .05) when compared with MCs treated with PBS.
Moreover, when compared with LPS conditions, changes in the
number of genes marked as differentially expressed were dra-
matic. When comparing LPS versus NAD1 conditions, 6053
genes were significantly upregulated, and 5845 were found to
be downregulated, suggesting that NAD1 signaling machinery
is distinct from LPS stimulation. As expected, dramatic changes
in gene expression were observed when comparing PBS with
LPS treatment (Fig 4, A).
To elucidate potential genes involved in MC-mediated CD41
T-cell differentiation, we investigated the role of the most upregu-
lated genes in NAD1 versus PBS conditions and compared them
with gene expression characteristics in presence of LPS (Fig 4,B).
FIG 3. MCs play a central role in NAD1-mediated CD41 T-cell differentiation. C57BL/6 WT and WBB6F1/
JKitw/Kitw-v (MC-deficient) mice were treated daily with intraperitoneal injection of 40 mg of NAD1 or a
placebo solution (PBS), as indicated. After 7 days, mice were killed, and systemic levels of CD41IFN-g1,
CD41IL-41, and CD41IL-17A1 cells were assessed by using flow cytometry. Data were derived from 2
independent experiments (n 5 5-10). Data represent means 6 SDs. ANOVA was used to compare groups:
***P < .001. APC, Allophycocyanin; PE, phycoerythrin.
J ALLERGY CLIN IMMUNOL
VOLUME 142, NUMBER 6
RODRIGUEZ CETINA BIEFER ET AL 1901
FIG 4. Unique MC gene expression profile after NAD1 activation. BMMCs from C57BL/6 mice were cultured
in the presence of NAD1 (500 mmol/L), LPS (10 mg/mL; Escherichia coli O127:B8), or placebo (PBS). After
16 hours of culture, cells were collected and RNAwas extracted for RNA-sequencing analysis. A,Differential
gene expression. B, Gene heat map expression profile. C, Ingenuity Pathway Analysis.
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Among the first 10 genes upregulated in PBS versus NAD1 con-
ditions, a robust upregulation of autotaxin (Enpp2), dystrophia
myotonica protein kinase (DMPK), and FERM domain contain-
ing 5 (Frmd5) were specific to NAD1 conditions when compared
with PBS or LPS treatment. Both DMPK38,39 and FRMD540 pro-
teins have been implicated in stabilizing cell membranes and cy-
toskeletons. Autotaxin has been shown to play a role in T-cell
activation and chemotaxis,41,42 and MCs have been shown to be
able to produce autotaxin.43 Furthermore, Ingenuity Pathway
Analysis predicted significant perturbations by NAD1 of other
signaling molecules involved in MC activation, such as TNFAIP2
or IKBKG (NEMO; Fig 4, C). It is well established that the ec-
toenzyme autotaxin generates lysophosphatidic acid (LPA), a
potent lipid mediator that acts on a series of specific G protein–
coupled receptors through hydrolysis of lysophosphatidylcho-
line.41 LPA can be produced by a myriad of different cell types
that include postmitotic neurons, adipocytes, MCs, and other
lymphoid cells. Autotaxin has been recently described as regu-
lating cytokine production, and autotaxin-LPA pathways have
been shown to play a critical role in asthmatic patients.44 Both hu-
man and murine T cells express LPA receptors,45,46 and LPA has
been found to inhibit TCR-mediated calcium mobilization.47
Collectively, our results indicate that MC activation by NAD1
triggers a unique gene expression profile that is distinct from LPS
stimulation and suggests the existence of an alternative pathway
that remains to be determined.
MCs induce T-cell differentiation in MHC class II2/2
and WASP2/2 mice after NAD1 administration
Our findings indicate that NAD1 promotes CD41 T-cell differ-
entiation through MCs and in the absence of antigen and TCR
activation. Thus we next sought to determine the role of MHC
class II and TCR molecules in NAD1-MC–mediated CD41 T-
cell differentiation. MHC class II2/2 mice were treated daily
with NAD1 or a placebo solution (PBS). After 7 days, flow cy-
tometry showed that NAD1 was able to promote a significant in-
crease in CD41IFN-g1, CD41IL-41, and CD41IL-171T cells in
MHC class II–deficient mice (see Fig E6, B).
In addition, WASP2/2 mice, which are known to have an
altered TCR activation and cytokine production, in particular
IFN-g,48 were used to assess the role of TCR in NAD1-MC–
mediated CD41 T-cell differentiation. Thus WASP2/2 mice
were treated daily with intraperitoneal injection of NAD1 or
PBS to assess whether NAD1-MC–mediated CD41 T-cell differ-
entiation could promote IFN-g production also in the context of
immunodeficiency. The results indicated that NAD1 was able
to promote a robust increase in CD41IFN-g1, CD41IL-41, and
CD41IL-171 T-cell frequencies in WASP2/2 mice when
compared with the control group (see Fig E6, C). Collectively,
our results suggest that NAD1-MC–mediated CD41T-cell differ-
entiation is functional, even in the absence of MHC class II or
with altered TCR activation.
Daily NAD1 treatment protects against lethal doses
of L monocytogenes through MCs exclusively
WT mice were pretreated for 5 consecutive days with NAD1
before infection with a nonlethal dose of L monocytogenes to
test whether regulation of innate and adaptive immune cells
throughMCs after NAD1 administration had a physiologic effect.
In addition, a control group of animals was pretreated with PBS
before infection. Mice treated with PBS had only a modest loss
of weight, did not exhibit signs of lethargy or gained weight
7 days after infection, and showed 100% survival (Fig 5, A)
when infected with a nonlethal dose of L monocytogenes. In
contrast, mice pretreated with NAD1 before infection (nonlethal
dose) had a more pronounced loss of weight, exhibited lethargy,
and were very susceptible to infection with an 80% mortality
rate (Fig 5, A).
Thus we tested whether MCs play a role in L monocytogenes
infection survival outcome after NAD1 administration. Indeed,
KitW/KitWv MC–deficient mice showed improved survival
compared with NAD1-treated WT mice. In contrast to WT
mice pretreated with NAD1, KitW/KitWv transgenic mice had
only a modest loss of weight and did not exhibit signs of lethargy.
More importantly, KitW/KitWv mice pretreated with NAD1
showed an 80% survival rate (Fig 5, A), confirming our in vivo
and in vitro findings and indicating that MCs play a central role
in the capacity of NAD1 to regulate innate and adaptive immu-
nity. Furthermore, we tested another set of MC-deficient mice
(KitWsh/KitWsh) in the context of L monocytogenes infection.
Similar to KitW/KitWv mice, KitWsh/KitWsh mice exhibited a
100% survival rate with no sign of lethargy. Collectively,
NAD1-mediated CD41 T-cell differentiation dramatically
altered the immune responses through MCs and significantly
affected physiologic functions of protection against bacterial
infection.
Our results indicated that pretreatment with NAD1 promoted
TH1, TH2, and TH17 CD4
1 T-cell subsets. Because TH1 has
been shown to play a protective role in L monocytogenes infec-
tion,35 we initially expected NAD1 pretreatment to protect
mice after bacterial infection. However, we could not rule out
that continuous NAD1 treatment might be required to sustain a
robust TH1 response. Thus we assessed whether prolonged and
continuous treatment with NAD1 could provide protection
against L monocytogenes infection. As shown in Fig 5, B, WT
mice continuously treated with NAD1 exhibited resistance
(>60% survival rate) to even lethal doses of L monocytogenes
when compared with the control group of mice that exhibited a
100% mortality rate. Consistent with our previous findings,
NAD1-mediated protection against lethal doses of L monocyto-
genes was abolished in both KitW/KitWv and KitWsh/KitWsh MC2/2
mice. We have shown previously that NAD1 regulates CD41
T-cell differentiation through a pathway distinct of well-
established transcription factors.25 In addition, we showed that
NAD1 altered dramatically differentiated TH1 and TH2 CD4
1
T cells by repressing their cytokine production and transcription
factors.25 More importantly, second stimulation of differentiated
TH1 and TH2 CD4
1 T cells was profoundly altered when
they were cultured in the presence of NAD1 after first
stimulation.25
Thus we next investigated whether pretreatment with NAD1
altered the classical CD41 T-cell differentiation pathway,36
specifically in CD41IFN-g1 T cells that have been shown to be
essential for host resistance to L monocytogenes infection. We
assessed whether NAD1 altered frequencies of CD41T-bet1 T
cells. Mice pretreated with NAD1 had lower frequencies and
total numbers of CD41IFN-g1T-bet1 cells when compared
with mice treated with a placebo solution (see Fig E7, A, in this
article’s Online Repository at www.jacionline.org). Although
treatment with NAD1 resulted in downregulation of T-bet
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expression, CD41 T cells frommice treated with NAD1mounted
robust IFN-g production (see Fig E7, B), which was consistent
with our previous studies.24,25 Although CD41IFN-g1 T-cell
responses remained similar in NAD1- and placebo-treated
mice, continuous treatment with NAD1 promoted host
protection against a lethal dose of L monocytogenes. In addition,
NAD1 affected the regulation and function of other important
immune cells, such as MCs and, more importantly, DCs. Thus
we investigated whether NAD1 promotes IFN-g production
that is not mediated by CD41 T cells. Our results indicated that
mice treated with NAD1 exhibited a significant increase in
IFN-g production by non-CD41 T cells, suggesting that NAD1
can promote IFN-g production by other non-CD41 lymphocytes
(see Fig E7, C). Taken together, our results indicate that
continuous treatment with NAD1 promotes robust IFN-g
production and protects against lethal doses of L monocytogenes
through MCs exclusively.
Pretreatment with NAD1 renders mice susceptible
to sublethal doses of L monocytogenes by
dampening the MCH class II–TCR pathway
Our data indicate that mice pretreated with NAD1 are suscep-
tible to sublethal doses of L monocytogenes, whereas continuous
treatment protects against lethal doses. Thus we next investigated
how pretreatment with NAD1 rendered mice susceptible to a sub-
lethal dose of bacteria.
Because antigen presentation through the MHC class II cell-
surface molecule is crucial in CD41 T-cell responses and our re-
sults indicated that NAD1 promotes CD41 T-cell differentiation
in the absence of MHC class II molecules, we investigated the ef-
fect of NAD1 pretreatment on MHC class II expression of
CD11b1CD11c1 DCs after L monocytogenes infection. The re-
sults indicated that pretreatment with NAD1 resulted in a dra-
matic decrease in MHC class II expression when compared
with the control group (see Fig E7, D), indicating that NAD1
FIG 5. MCsmediate protection against lethal doses of Lmonocytogenes during daily NAD1 administration.
C57BL/6 WT, KitW/KitW-v, and kitWsh/KitWsh MC-deficient mice were pretreated for 5 consecutive days with
daily intraperitoneal injections of NAD1 (40 mg) or placebo solution (PBS). A, Mice were then infected
with an intraperitoneal nonlethal dose (1 3 107 colony-forming units) of viable L monocytogenes. B,
C57BL/6 WTmice were pretreated for 5 consecutive days with NAD1 (40 mg administered intraperitoneally)
or placebo solution (PBS) before infection.WTmice were then treated daily with NAD1 (40mg administered
intraperitoneally) or placebo solution (PBS) after a lethal dose (1 3 108 colony-forming units) of viable L
monocytogenes. Weight loss and survival after infection were monitored. Data were derived from 3 inde-
pendent experiments (n 5 5-10 per group). Data represent means 6 SDs. ns, Not significant. ANOVA and
log-rank tests were used to compare groups, respectively.
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FIG 6. NAD1 regulates T-cell differentiation through a novel MC-dependent signaling pathway. MC-
mediated CD41 T-cell differentiation after NAD1 administration does not require antigen presentation
through major APCs and MHC class II.
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dampens antigen presentation capacities of DCs after L monocy-
togenes infection. WT mice pretreated for 5 consecutive days
with NAD1 before infection with a nonlethal dose of L monocy-
togenes had amore pronounced loss of weight, exhibited lethargy,
and were very susceptible to infection with an 80% mortality rate
(Fig 5, A). In contrast, WTmice continuously treated with NAD1
exhibited resistance (>60% survival rate) to even lethal doses of L
monocytogenes when compared with the control group of mice
that exhibited a 100% mortality rate (Fig 5, B).
Collectively, our results indicate that pretreatment with NAD1
will trigger the NAD1-MC pathway while dampening the APC–
MHC class II–TCR signaling machinery, suggesting that discon-
tinuous administration of NAD1 can subject the animals to an
immunodeficient state that renders them susceptible to sublethal
doses of L monocytogenes. Collectively, our results indicate
that NAD1 profoundly alters, in the absence of antigen, innate
and adaptive immune responses through MCs exclusively and
independently from the classical DC/MHC class II antigen pre-
sentation machinery that results in significant physiologic
changes (Fig 6).
DISCUSSION
Our previous studies have demonstrated a novel role for NAD1
in regulating T-cell fate in the context of antigen-specific re-
sponses.24,25 However, whether NAD1mechanisms of action op-
erate in an antigen-independent manner and whether NAD1
affects other immune cells remained unknown. APCs, in partic-
ular DCs, have been considered the most potent immune cells
to prime naive CD41 T cells. In addition to their capacity for an-
tigen processing and presentation to the TCR through MHC class
II cell-surface molecules, DCs can regulate CD41 T-cell activa-
tion through costimulatory molecules and a myriad of secreted
cytokines and chemokines.8 Moreover, it has been reported that
recognition of conserved PAMPs, such asmicrobial nucleic acids,
lipoproteins, and carbohydrates, or DAMPs, which are released
from injured, through intracellular or distinct PRRs expressed
on DCs contribute to pathogen-specific CD41 T-cell responses.12
Thus DCs and antigen presentation are regarded as fundamentally
required and play a central role in CD41 T-cell activation and dif-
ferentiation and are considered the bridge between innate and
adaptive immune responses.1,7,8,49 These observations are widely
supported by studies based on transgenic animals with alteration
in MHC class II, TCR, and DC depletion and confirmed in immu-
nodeficient patients.50,51
Here we demonstrated that NAD1, a natural cofactor, induces
CD41 differentiation in the absence of antigen presentation,
MHC class II expression, and absence of TCR activation. Further-
more, we demonstrate that effects of NAD1 are not mediated by
major APCs, including DCs, but throughMCs exclusively. More-
over, our study indicated that major costimulatory molecules are
not involved in NAD1-MC–mediated CD41 T-cell differentia-
tion, suggesting that MCs deliver T-cell stimulation through an
alternative pathway. This is in line with previous studies indi-
cating that MCs cannot prime naive CD41 T cells, most likely
because of an altered costimulatory molecule expression.8
Furthermore, previous studies have reported that MCs express
MHC class II molecules; however, it has been found to be seques-
tered mainly in lysosomal intracellular compartments.22 This is
consistent with our findings indicating that NAD1-MC–mediated
CD41 T-cell differentiation does not require antigen presentation
or MHC class II molecules.
The cofactor ATP is well recognized for its role as a source of
high energy and in cellular metabolism; however, when released
from cells after cellular damage, ATP acts as a DAMP signal.
DAMP signaling is mainly mediated through the PRRs that are
expressed on APCs, in particular DCs and macrophages.52
Although the primary function of PRRs is to mediate innate im-
mune responses to pathogen invasion and tumors, increasing ev-
idence has shown their role in the development of autoimmune
and chronic inflammation52 by promoting TH17 responses. ATP,
for instance, has been shown to convert CD41CD251Foxp31
regulatory T cells into TH17 cells and to promote colitis by
enhancing the TH17 proinflammatory subset in the lamina propria
throughDCs.32,53 Similar to ATP, NAD1, which is also a cofactor,
has been described for its role in energy metabolism and more
recently in aging.54-56 In contrast to ATP, NAD1-mediated innate
and adaptive immune regulation was intermediated by MCs and
was independent of major APCs, including DCs and macro-
phages. Moreover, our previous studies have underscored the
robust immunosuppressive properties of NAD1 by promoting a
systemic increase in IL-10 cytokine levels through regulatory
type 1 cells.24,25 We have also shown that NAD1 regulates
CD41 T-cell fate in the absence of major transcription factors.
Indeed, NAD1 was able to promote a robust TH1 response in
the absence of T-bet, a transcription factor considered indispens-
able for TH1 differentiation and IFN-g production.
25 In contrast to
proinflammatory responses induced by DAMPs, including ATP,
NAD1 protects against autoimmune diseases and promotes allo-
graft survival.24,25 Furthermore, our RNA-sequencing analysis
indicated that treatment with NAD1 resulted in upregulation of
a distinct set of genes when compared with LPS, a prototypical
PAMP, suggesting that NAD1 triggered a different signaling
pathway that remains yet to be determined in detail.
In line with our previous reports, NAD1 treatment downregu-
lated T-bet expression but did not alter CD41IFN-g1 T-cell re-
sponses when compared with those in the control group of
mice. Although CD41IFN-g1 T-cell responses remained similar
in NAD1 and placebo-treated mice, continuous treatment with
NAD1 conferred host protection against L monocytogenes. Previ-
ous studies have underscored the critical role of IFN-g in host pro-
tection against L monocytogenes.9,57 Thus NAD1 might mediate
host protection by promoting IFN-g production by other immune
cells, such as CD81 cells or innate lymphoid cells. Although our
study emphasizes the potent role of NAD1 on many immune
cells, such as CD41 T cells, MCs, and DCs, its effect on other
important immune cells, such as B cells, CD81 cells, and innate
lymphoid cells, remain yet to be determined, and its role in other
inflammatory conditions or infections, including viral infections,
requires further investigation.
More importantly, our study unravels a novel cellular mech-
anism that regulates CD41T-cell differentiation, a process known
to play a central role in many inflammatory conditions.58 NAD1-
mediated immune changes in the absence of antigen had a robust
physiologic effect after bacterial infection. Indeed, NAD1-pre-
treated mice were highly susceptible to even a nonlethal dose of
bacterial infection that resulted in high mortality. In contrast,
maintenance of NAD1 signaling machinery by continuous treat-
ment with NAD1 conferred host protection after infection. More
importantly, NAD1 treatment altered T-bet expression and MHC
class II expression on CD11c1 DCs, suggesting that the NAD1-
MC–mediated CD41 T-cell differentiation pathway might not
only promote robust host protection against bacterial infection
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but also might be distinct from the classical DC–MHC class II–
TCR pathway. Indeed, with clodronate administration, DTR
transgenic and MC-deficient mice (KitW/KitW-v), and BMMCs,
we demonstrated that NAD1-MC–mediated CD41 T-cell
differentiation is independent of the classical DC–MHC class
II–TCR pathway. More importantly, our data indicated that in
the presence of NAD1, MCs mediated differentiation of both mu-
rine and human CD41 T cells. These findings suggest that NAD1
can pave the way for novel therapies in the context of microbial
infections or primary immunodeficiencies that are characterized
by altered DC–MHC class II–TCR signaling machinery.
In summary, our study demonstrates the emerging role of
NAD1 as a new paradigm in innate and adaptive immune re-
sponses with its unique property as an MC-mediated immune
regulator that is distinct from the classical APC–MHC class II–
TCR pathway.
Key messages
d NAD1 alone regulates CD41 T-cell fate in the absence of
antigen.
d NAD1 regulates CD41 T-cell fate independently of major
APCs and MHC-TCR signaling machinery.
d Mast cells exclusively regulate CD41 T-cell differentiation
after NAD1 administration.
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FIG E1. High doses of NAD1 do not promote naive CD41 T-cell differentiation in vitro, and NAD1 regulates
CD11b1CD11c1 DC cytokine production in vitro in a dose-dependent manner. A, Sorted naive
CD41CD442CD62L1 T cells were isolated from spleens of C57BL/6 mice and cultured in complete media
with increasing concentrations of NAD1 (500 mmol/L and 1 mmol/L) or PBS. After 96 hours, frequencies
of CD41IFN-g1, CD41IL-41, and CD41IL-17A1 cells were assessed by using flow cytometry (n 5 10). Data
were derived from 3 independent experiments. B, Sorted CD11b1CD11c1 DCs were isolated from spleens
of C57BL/6 mice and cultured (1 3 106 cells/well) in complete media and in the presence of increasing con-
centrations of NAD1 (100 mmol/L and 500 mmol/L). As a positive control, CD11b1CD11c1 DCs were cultured
in the presence of LPS (1 mg/mL). After 16 hours of culture, cells were collected, andmRNA expression levels
of IL-1a, IL-1b, IL-6, IL-10, IL-12, IL-23, TGF-b, TNF-a, TLR2, and TLR4 were determined by using real-time
PCR. Values are expressed as fold expression relative to the housekeeping gene glyceraldehye-
3-phosphate dehydrogenase (GAPDH; n 5 5). Data were derived from 2 different experiments. ns, Not
significant. *P < .05, **P < .01, and ***P < .001, as determined bymeans of ANOVA, comparing the indicated
groups. Data represent means 6 SDs. APC, Allophycocyanin; PE, phycoerythrin.
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FIG E2. In vivo depletion of DCs by means of liposomal clodronate administration does not alter NAD1-
mediated CD41 T-cell differentiation. A, C57BL/6 WT, MC2/2, and Rag22/2gc2/2 mice were treated intrave-
nously with liposomal clodronate at 28 days, 25 days, and 21 day before NAD1 treatment. Data derived
from 2 independent experiments (n 5 5 per group). B, C57BL/6 WT mice were treated intravenously with
liposomal clodronate at 28 days, 25 days, and 21 day before NAD1 treatment. Mice were then treated
with daily intraperitoneal injections of 40 mg of NAD1 or a placebo solution (PBS). After 7 days, mice
were killed, and frequencies of CD41IFN-g1, CD41IL-41, and CD41IL-17A1 cells were analyzed by using
flow cytometry. Data were derived from 2 independent experiments (n 5 10). Data represent
means 6 SDs. ns, Not significant. The Student t test and ANOVA were used to compare between groups:
**P < .01 and ***P < .001. APC, Allophycocyanin; PE, phycoerythrin; SSC, side scatter.
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FIG E3. NAD1 promotes T-cell differentiation in Rag22/2gc2/2mice and flow cytometry of in vitro differen-
tiation of BMMCs. A, Rag22/2gc2/2mice were treated intravenously with liposomal clodronate at 28 days,
25 days, and21 day before NAD1 treatment. After depletion, sorted naive CD41CD442CD62L1 T cells from
C57BL/6 WT mice sorted by means of fluorescence-activated cell sorting were adoptively transferred
(3 3 106 cells per adoptive transfer). Animals were then treated with daily intraperitoneal injections of
40 mg of NAD1 or a placebo solution (PBS). After 7 days, mice were killed, spleens were collected, and fre-
quencies of CD41IFN-g1, CD41IL-41, and CD41IL-17A1 cells were assessed by using flow cytometry. Data
were derived from 2 independent experiments (n 5 10). B, CD11b-DTR transgenic mice weighing 25 to
30 g were injected with diphtheria toxin (DT; 25 ng/g body weight) 24 hours before and 72 hours after begin-
ning NAD1 or PBS administration for depletion of CD11b1 cells. After 7 days of treatment with PBS or NAD1,
frequencies of CD41IFN-g1, CD41IL-41, and CD41IL-17A1 cells were assessed by using flow cytometry. Data
were derived from 2 independent experiments (n5 10). C, BMMCs were obtained from femurs and tibias of
6- to 8-week-old C57BL/6 WTmice. BMMCs were cultured inWEHI-3–conditionedmedium over 90 days. Pu-
rities of c-Kit1FcεRI1 MCs were then assessed by using flow cytometry. Data represent means 6 SDs. The
Student t test was used to compare between groups: *P < .05 and **P < .01. APC, Allophycocyanin; PE,
phycoerythrin; SSC, side scatter.
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FIG E4. Murine MCs promote CD41IFN-g1, CD41IL-41, and CD41IL-17A1 T-cell differentiation in the pres-
ence of NAD1 both with and without cell-cell contact. BMMCs were cocultured with isolated naive
CD41CD442CD62L1 T cells from C57BL/6 mice (1:100 ratio) either in cell-cell contact or in separate compart-
ments by using a transwell system. Cells were then treated with NAD1 (500 mmol/L) or PBS. After 96 hours,
frequencies of CD41IFN-g1 (A), CD41IL-41 (B), and CD41IL-17A1 (C) cells were assessed by using flow cy-
tometry (n 5 6). Data were derived from 2 independent experiments. *P < .05, **P < .01, and ***P < .001,
as determined by means of ANOVA, comparing the indicated groups. Data represent means 6 SDs. APC,
Allophycocyanin; FITC, fluorescein isothiocyanate; PE, phycoerythrin.
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FIG E5. MCs do not regulate CD41 T-cell differentiation in the presence of NAD1 through CD80. A, BMMCs
from C57BL/6 mice were cultured in the presence of NAD1 (500 mmol/L) or placebo (PBS). After 24 hours of
culture, cells were collected, and mRNA was extracted. mRNA levels of CD86, CD80, TNF-a, IL-4, inducible
costimulator ligand (ICOS-L), OX40 ligand (OX40-L), IL-6, and IL-33 were determined by using real-time PCR.
Values are expressed as fold expression relative to the housekeeping gene glyceraldehye-3-phosphate de-
hydrogenase (GAPDH). B and C, BMMCs were cocultured with isolated naive CD41CD442CD62L1 T cells
from C57BL/6 mice (1:100 ratio) in cell-cell contact conditions in the presence of a-CD80, NAD1
(500 mmol/L), or placebo (PBS), as indicated. B-D, After 96 hours, frequencies of CD41IFN-g1 (Fig E5, B),
CD41IL-17A1 (Fig E5, C), and CD41IL-41 (Fig E5, D) cells were assessed by using flow cytometry (n 5 6).
Data were derived from 2 independent experiments. ns, Not significant. *P < .05, **P < .01, and
***P < .001, as determined by using the Student t test and ANOVA, comparing the indicated groups.
Data represent means 6 SDs. APC, Allophycocyanin; FITC, fluorescein isothiocyanate; PE, phycoerythrin.
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FIG E6. Conserved MC-mediated CD41 T-cell differentiation in the human MC line LAD-2 in the presence of
NAD1. NAD1 induces T-cell differentiation in MHC class II2/2 and WASP2/2 mice. A, Human MC line LAD-
2 cells were cocultured with isolated human naive CD41 T cells from healthy donors (1:100 ratio) either in
cell-cell contact or in separate compartments by using a transwell system. Cells were then treated with
NAD1 (500 mmol/L) or PBS. After 96 hours, frequencies of CD41IFN-g1 cells were assessed by using flow
cytometry (n 5 6). Data were derived from 2 independent experiments. B, MHC class II2/2 (B6.129S-
H2dlAb1-Ea) mice were treated daily with intraperitoneal injections of 40 mg of NAD1 or a placebo solution
(PBS). After 7 days, mice were killed, and splenocytes were harvested. Systemic frequencies of CD41IFN-
g1, CD41IL-41, and CD41IL-17A1 cells were analyzed by means of flow cytometry. Data were derived
from 2 independent experiments (n 5 5). C, WASP2/2 (B6.129S6-Wastm1Sbs/J) mice were treated daily
with intraperitoneal injections of 40 mg of NAD1 or a placebo solution (PBS). After 7 days, mice were killed,
and frequencies of CD41IFN-g1, CD41IL-41, and CD41IL-17A1 cells were assessed by means of flow cytom-
etry. Data were derived from 2 independent experiments (n5 5). ns, Not significant. *P < .05, **P < .01, and
***P < .001, as determined by using the Student t test and ANOVA, comparing the indicated groups. Data
represent means 6 SDs. APC, Allophycocyanin; FITC, fluorescein isothiocyanate; PE, phycoerythrin; SSC,
side scatter.
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FIG E7. NAD1 alters systemic frequencies of CD41T-bet1IFN-g1 cells and CD11c1MHC class II1 DCs after L
monocytogenes infection. C57BL/6 mice were treated for 5 days with daily intraperitoneal injections of
NAD1 (40 mg) or placebo solution (PBS). After 5 days, mice were infected with a nonlethal dose of L mono-
cytogenes (13 107 colony-forming units) and killed 3 days later. Spleens were collected, and frequencies of
CD41T-bet1IFN-g1 (A), CD41IFN-g1 (B), and CD42IFN-g1 (C) T cells and CD11b1CD11c1MHC class II1 DCs
(D) were assessed by using flow cytometry. Data were derived from 2 independent experiments (n 5 5).
Data represent means 6 SDs. ns, Not significant. The Student t test was used to compare between groups:
*P < .05 and ***P < .001.
J ALLERGY CLIN IMMUNOL
VOLUME 142, NUMBER 6
RODRIGUEZ CETINA BIEFER ET AL 1908.e7
